Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 721-730 of 2762 for cancer

Edit search filters
  1. MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

    Rochester, MN

  2. Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

  3. Brightline-1: A Study to Compare Bi 907828 With Doxorubicin In People With a Type of Cancer Called Dedifferentiated Liposarcoma

    Jacksonville, FL, Rochester, MN

  4. A Study to Evaluate the Safety and Effectiveness of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

    Rochester, MN

  5. Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

    Rochester, MN

  6. Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

    Rochester, MN

  7. Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study to Evaluate HH2853 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  9. The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. 177Lu-DTPA-Omburtamab Radioimmunotherapy toTreat Recurrent or Refractory Medulloblastoma

.

Mayo Clinic Footer